PE20201287A1 - Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso - Google Patents
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de usoInfo
- Publication number
- PE20201287A1 PE20201287A1 PE2020000671A PE2020000671A PE20201287A1 PE 20201287 A1 PE20201287 A1 PE 20201287A1 PE 2020000671 A PE2020000671 A PE 2020000671A PE 2020000671 A PE2020000671 A PE 2020000671A PE 20201287 A1 PE20201287 A1 PE 20201287A1
- Authority
- PE
- Peru
- Prior art keywords
- angptl3
- irna agents
- compositions
- methods
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgacion se refiere a agentes de iARN, por ejemplo, agentes de iARN de cadena doble, capaces de inhibir la expresion del gen de la Angiopoyetina tipo 3 (tambien denominada ANGPTL3, ANGPL3, proteina angiopoyetina tipo 3), y composiciones que incluyen agentes de iARN de ANGPTL3. Tambien se divulgan metodos para usar los agentes iARN de ANGPTL3 y composiciones. Los agentes iARN de ANGPTL3 divulgados en la presente pueden estar conjugados con ligandos de direccionamiento para facilitar la administracion a celulas, inclusive a hepatocitos. Tambien se describen composiciones farmaceuticas que incluyen uno o mas agentes de iARN de ANGPTL3, opcionalmente con uno o mas productos terapeuticos adicionales. La administracion de los agentes de iARN de ANGPTL3 in vivo proporciona la inhibicion de la expresion del gen ANGPTL3, y puede dar como resultado niveles de trigliceridos y/o niveles de colesterol reducidos en el sujeto. Los agentes de iARN se pueden usar en metodos de tratamiento de enfermedades y trastornos relacionados con ANGPTL3 que incluyen enfermedades cardiovasculares, tales como hipertrigliceridemia e hiperlipidemia
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558819P | 2017-09-14 | 2017-09-14 | |
US201762583919P | 2017-11-09 | 2017-11-09 | |
US201862651284P | 2018-04-02 | 2018-04-02 | |
US201862694976P | 2018-07-07 | 2018-07-07 | |
PCT/US2018/050848 WO2019055633A1 (en) | 2017-09-14 | 2018-09-13 | RNAI AGENTS AND COMPOSITIONS FOR INHIBITING ANALOGUE EXPRESSION OF ANGIOPOIETIN 3 (ANGPTL3) AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20201287A1 true PE20201287A1 (es) | 2020-11-24 |
Family
ID=65630620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000671A PE20201287A1 (es) | 2017-09-14 | 2018-09-13 | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso |
Country Status (22)
Country | Link |
---|---|
US (2) | US10995335B2 (es) |
EP (1) | EP3681513A4 (es) |
JP (2) | JP7281452B2 (es) |
KR (1) | KR20200044837A (es) |
CN (2) | CN117701562A (es) |
AU (1) | AU2018331383A1 (es) |
BR (1) | BR112020003126A2 (es) |
CA (1) | CA3074320A1 (es) |
CL (1) | CL2020000666A1 (es) |
CO (1) | CO2020001740A2 (es) |
EC (1) | ECSP20018305A (es) |
IL (1) | IL273173A (es) |
JO (1) | JOP20200050A1 (es) |
MX (1) | MX2020001912A (es) |
PE (1) | PE20201287A1 (es) |
PH (1) | PH12020500309A1 (es) |
SG (1) | SG11201912188RA (es) |
TN (1) | TN2020000038A1 (es) |
TW (1) | TWI823866B (es) |
UY (1) | UY37881A (es) |
WO (1) | WO2019055633A1 (es) |
ZA (1) | ZA202103669B (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2711799C2 (ru) | 2011-06-21 | 2020-01-22 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
KR20230115344A (ko) * | 2016-09-02 | 2023-08-02 | 애로우헤드 파마슈티컬스 인코포레이티드 | 표적화 리간드 |
DK3607069T3 (da) | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
TW202132567A (zh) | 2019-11-01 | 2021-09-01 | 美商阿尼拉製藥公司 | 亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法 |
KR20220115946A (ko) | 2019-11-13 | 2022-08-19 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물 |
AU2020402885A1 (en) | 2019-12-13 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (C9orf72) iRNA agent compositions and methods of use thereof |
WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
WO2021167841A1 (en) | 2020-02-18 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
CA3174725A1 (en) | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
EP4121536A1 (en) | 2020-03-18 | 2023-01-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting angptl3 expression |
TW202204615A (zh) | 2020-03-26 | 2022-02-01 | 美商阿尼拉製藥公司 | 冠狀病毒iRNA組成物及其使用方法 |
TW202202153A (zh) * | 2020-03-26 | 2022-01-16 | 美商艾羅海德製藥公司 | 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法 |
EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
BR112022021813A2 (pt) | 2020-04-27 | 2023-01-17 | Alnylam Pharmaceuticals Inc | Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas |
JP2023523790A (ja) | 2020-04-30 | 2023-06-07 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 補体因子B(CFB)iRNA組成物およびその使用方法 |
EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
IL299063A (en) | 2020-06-18 | 2023-02-01 | Alnylam Pharmaceuticals Inc | Xanthine dehydrogenase (xdh) RNA compositions and methods of using them |
WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
CN116333013A (zh) * | 2020-09-30 | 2023-06-27 | 纳肽得(青岛)生物医药有限公司 | 一种靶向配体 |
TW202229552A (zh) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法 |
CN116887842A (zh) * | 2020-10-16 | 2023-10-13 | 赛诺菲 | 用于抑制angptl3的新型rna组合物和方法 |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
AU2021380809A1 (en) | 2020-11-13 | 2023-06-22 | Alnylam Pharmaceuticals, Inc. | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
EP4274896A1 (en) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Complement component 9 (c9) irna compositions and methods of use thereof |
KR20230146048A (ko) | 2021-02-12 | 2023-10-18 | 알닐람 파마슈티칼스 인코포레이티드 | 슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법 |
EP4298220A1 (en) | 2021-02-25 | 2024-01-03 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods of use thereof |
JP2024515423A (ja) | 2021-02-26 | 2024-04-10 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法 |
CA3212128A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
KR20230162024A (ko) | 2021-03-29 | 2023-11-28 | 알닐람 파마슈티칼스 인코포레이티드 | 헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법 |
WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
IL307926A (en) | 2021-04-26 | 2023-12-01 | Alnylam Pharmaceuticals Inc | Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them |
JP2024519293A (ja) | 2021-04-29 | 2024-05-10 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法 |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
TW202317762A (zh) | 2021-06-02 | 2023-05-01 | 美商艾拉倫製藥股份有限公司 | 含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法 |
BR112023025224A2 (pt) | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos |
AR126070A1 (es) | 2021-06-08 | 2023-09-06 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4) |
KR20240026203A (ko) | 2021-06-30 | 2024-02-27 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물 |
TW202333748A (zh) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物 |
WO2023003922A1 (en) | 2021-07-21 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Metabolic disorder-associated target gene irna compositions and methods of use thereof |
AU2022316139A1 (en) | 2021-07-23 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
EP4377458A1 (en) | 2021-07-29 | 2024-06-05 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
CN117795074A (zh) | 2021-08-03 | 2024-03-29 | 阿尔尼拉姆医药品有限公司 | 转甲状腺素蛋白(TTR)iRNA组合物和其使用方法 |
WO2023014765A1 (en) | 2021-08-04 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT) |
TW202334413A (zh) | 2021-08-13 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 第十二因子(F12)iRNA組成物及其使用方法 |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
CA3232420A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
CN116888263A (zh) * | 2021-09-23 | 2023-10-13 | 上海舶望制药有限公司 | 用于抑制血管生成素样3(angptl3)蛋白表达的组合物和方法 |
AU2022364838A1 (en) | 2021-10-15 | 2024-04-11 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
TW202333749A (zh) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 補體因子b(cfb)irna組成物及其使用方法 |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
AU2022395876A1 (en) * | 2021-11-29 | 2024-05-09 | Shanghai Argo Biopharmaceutical Co., Ltd. | Composition and method for inhibiting expression of hepatitis b virus (hbv) protein |
WO2023122656A1 (en) | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
WO2023134705A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海金中锘美生物医药科技有限公司 | 抑制angptl3表达的rna干扰剂及其用途 |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023196941A1 (en) * | 2022-04-08 | 2023-10-12 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
CN116987696A (zh) * | 2022-08-04 | 2023-11-03 | 北京福元医药股份有限公司 | 用于抑制angptl3基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
WO2024032608A1 (zh) * | 2022-08-08 | 2024-02-15 | 大睿生物医药科技(上海)有限公司 | 调控ANGPTL3基因活性的siRNA分子 |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
WO2024044542A2 (en) * | 2022-08-22 | 2024-02-29 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of angptl3-related diseases and disorders |
US20240158795A1 (en) | 2022-11-10 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Treatment Of Kidney Diseases With A Combination of Angiopoietin Like 3 (ANGPTL3) Inhibitors And Solute Carrier Family 5 Member 2 (SLC5A2) Inhibitors |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
MXPA01009073A (es) | 1999-03-10 | 2002-05-06 | Phogen Ltd | Suministro de acidos nucleicos y proteinas a las celulas. |
KR20020062652A (ko) | 1999-12-09 | 2002-07-26 | 상꾜 가부시키가이샤 | 고지혈증의 치료 또는 예방제의 시험방법 |
CN1615440A (zh) * | 2001-11-16 | 2005-05-11 | 杰南技术公司 | 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法 |
CA2881743A1 (en) * | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
US20070276134A1 (en) * | 2006-05-24 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and organic cations |
WO2008022309A2 (en) | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
CA2930393C (en) | 2007-12-04 | 2022-11-29 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
DK2504435T3 (da) * | 2009-11-26 | 2019-12-09 | Quark Pharmaceuticals Inc | Sirna-forbindelser omfattende terminale substitutioner |
CN106146591B (zh) * | 2010-01-08 | 2020-07-31 | Ionis制药公司 | 血管生成素样3表达的调节 |
ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
RU2711799C2 (ru) | 2011-06-21 | 2020-01-22 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
US8932572B2 (en) | 2011-08-26 | 2015-01-13 | Arrowhead Madison Inc. | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
EA201490993A1 (ru) * | 2011-11-18 | 2014-09-30 | Элнилэм Фармасьютикалз, Инк. | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи |
MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
EP3919620A1 (en) * | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
MX2016008462A (es) | 2013-12-24 | 2016-10-12 | Ionis Pharmaceuticals Inc | Modulacion de la expresion similar a la angiopoyetina tipo 3. |
BR122020024443B1 (pt) | 2014-05-01 | 2022-02-22 | Ionis Pharmaceuticals, Inc | Composto e composição farmacêutica para modulação da expressão de angptl3 |
CN114181942A (zh) | 2014-08-20 | 2022-03-15 | 阿尔尼拉姆医药品有限公司 | 经修饰的双链rna试剂 |
WO2016154127A2 (en) | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
TWI723986B (zh) * | 2015-04-13 | 2021-04-11 | 美商阿尼拉製藥公司 | 類血管生成素3(ANGPTL3)iRNA組成物及其用途方法 |
JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
KR20230048446A (ko) | 2016-03-07 | 2023-04-11 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
MA45340A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques du récepteur des androgènes et leurs utilisations |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
KR20230115344A (ko) | 2016-09-02 | 2023-08-02 | 애로우헤드 파마슈티컬스 인코포레이티드 | 표적화 리간드 |
-
2018
- 2018-09-13 CN CN202311448750.0A patent/CN117701562A/zh active Pending
- 2018-09-13 SG SG11201912188RA patent/SG11201912188RA/en unknown
- 2018-09-13 KR KR1020207007014A patent/KR20200044837A/ko not_active Application Discontinuation
- 2018-09-13 CN CN201880073901.XA patent/CN111343994B/zh active Active
- 2018-09-13 WO PCT/US2018/050848 patent/WO2019055633A1/en active Application Filing
- 2018-09-13 BR BR112020003126-7A patent/BR112020003126A2/pt unknown
- 2018-09-13 JO JOP/2020/0050A patent/JOP20200050A1/ar unknown
- 2018-09-13 AU AU2018331383A patent/AU2018331383A1/en active Pending
- 2018-09-13 TN TNP/2020/000038A patent/TN2020000038A1/en unknown
- 2018-09-13 EP EP18855310.1A patent/EP3681513A4/en active Pending
- 2018-09-13 US US16/130,377 patent/US10995335B2/en active Active
- 2018-09-13 MX MX2020001912A patent/MX2020001912A/es unknown
- 2018-09-13 CA CA3074320A patent/CA3074320A1/en active Pending
- 2018-09-13 JP JP2020514926A patent/JP7281452B2/ja active Active
- 2018-09-13 PE PE2020000671A patent/PE20201287A1/es unknown
- 2018-09-14 UY UY0001037881A patent/UY37881A/es unknown
- 2018-09-14 TW TW107132397A patent/TWI823866B/zh active
-
2020
- 2020-02-11 PH PH12020500309A patent/PH12020500309A1/en unknown
- 2020-02-14 CO CONC2020/0001740A patent/CO2020001740A2/es unknown
- 2020-03-09 IL IL273173A patent/IL273173A/en unknown
- 2020-03-12 EC ECSENADI202018305A patent/ECSP20018305A/es unknown
- 2020-03-13 CL CL2020000666A patent/CL2020000666A1/es unknown
-
2021
- 2021-04-15 US US17/231,479 patent/US20210238602A1/en active Pending
- 2021-05-28 ZA ZA2021/03669A patent/ZA202103669B/en unknown
-
2023
- 2023-02-27 JP JP2023028733A patent/JP2023054368A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023054368A (ja) | 2023-04-13 |
UY37881A (es) | 2019-03-29 |
CN111343994B (zh) | 2023-11-21 |
US10995335B2 (en) | 2021-05-04 |
JOP20200050A1 (ar) | 2020-03-05 |
PH12020500309A1 (en) | 2021-01-25 |
TWI823866B (zh) | 2023-12-01 |
CA3074320A1 (en) | 2019-03-21 |
US20210238602A1 (en) | 2021-08-05 |
EP3681513A1 (en) | 2020-07-22 |
BR112020003126A2 (pt) | 2020-10-13 |
WO2019055633A1 (en) | 2019-03-21 |
ECSP20018305A (es) | 2020-06-30 |
MX2020001912A (es) | 2020-03-24 |
CN111343994A (zh) | 2020-06-26 |
EP3681513A4 (en) | 2021-09-22 |
AU2018331383A1 (en) | 2020-04-23 |
JP7281452B2 (ja) | 2023-05-25 |
KR20200044837A (ko) | 2020-04-29 |
CO2020001740A2 (es) | 2020-05-29 |
TW201922264A (zh) | 2019-06-16 |
CL2020000666A1 (es) | 2020-08-14 |
ZA202103669B (en) | 2023-03-29 |
SG11201912188RA (en) | 2020-01-30 |
JP2020534268A (ja) | 2020-11-26 |
US20190078089A1 (en) | 2019-03-14 |
TN2020000038A1 (en) | 2021-10-04 |
CN117701562A (zh) | 2024-03-15 |
IL273173A (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20201287A1 (es) | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso | |
PE20201283A1 (es) | Agentes de iarn y composiciones para inhibir la expresion de la apolipoproteina c-iii (apoc3) | |
CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
CO2017004728A2 (es) | Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa) | |
BR112017011536A2 (pt) | terapias de combinação | |
PE20160030A1 (es) | COMPOSICIONES DE ARNi DE SERPINA 1 Y SUS METODOS DE USO | |
ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
AR113254A1 (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA ANGIOPOYETINA TIPO 3 (ANGPTL3) Y MÉTODOS DE USO | |
BR112017003467A2 (pt) | complexo platina (iv) com eficácia antitumoral aumentada | |
AR113014A1 (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3) | |
AR112754A1 (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO | |
AR106227A1 (es) | COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA) | |
CR20200117A (es) | Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso | |
AR113454A1 (es) | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 | |
EA202090717A1 (ru) | СРЕДСТВА И КОМПОЗИЦИИ РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA202090234A1 (ru) | СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ | |
AR103676A1 (es) | COMPOSICIONES DE ARNi QUE CONTIENEN UN DOMINIO FOSFOLIPASA TIPO PATATINA 3 (PNPLA3) Y SUS MÉTODOS DE USO | |
BR112014033118A8 (pt) | Combinações farmacêuticas de um inibidor de cdk4/6 e um inibidor de b-raf |